Digestive diseases and sciences · 2026
High-Dose Opioid Use Among Adolescents and Young Adults with Chronic Digestive Disorders.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yarlagadda Sishir, Huang Lynn, Dharanipragada Devyani, Younan Maria, Arshad Ali, Paniagua-Perez Deysi, Rech Megan A, Raval Mehul V, Balbale Salva N
Аннотация
BACKGROUND: High-dose opioid use (≥ 50 morphine milligram equivalents [MME]/day) is associated with increased risk of adverse outcomes, including overdose. We investigated the prevalence and risk factors for high-dose opioid use among adolescents and young adults (AYA) with inflammatory bowel disease (IBD) and other chronic digestive disorders to inform safer pain management strategies.
METHODS: This retrospective cohort study identified AYA aged 15-29 years with chronic digestive disorders who received ≥ 1 outpatient opioid prescription between March 2018 and December 2021, using Northwestern Medicine's Electronic Data Warehouse. Short-term persistent high-dose opioid use was defined as a daily mean of ≥ 50 MME/day for ≥ 7 consecutive days. Patients were categorized into high-dose vs. non-high-dose users. We examined demographic and clinical covariates (e.g., race/ethnicity, insurance status, psychiatric diagnoses, GI and non-GI pain diagnoses, concurrent medications) using descriptive and bivariate analyses. Risk factors for high-dose use were identified via multivariate logistic regression.
RESULTS: Among 2549 AYA patients, 12% met criteria for high-dose opioid use. Risk factors included older age within the cohort, benzodiazepine-opioid co-use, oxycodone use, and concurrent non-GI pain diagnoses (e.g., arthritis).
DISCUSSION: Nearly 12% of AYA with chronic digestive disorders who used opioids for ≥ 7 days received high-dose prescriptions. These findings underscore the need for safer prescribing guidelines tailored to this population. Future work should consider weight-based dosing thresholds and expanded datasets to monitor and reduce opioid-related harm in AYA with digestive disorders.
METHODS: This retrospective cohort study identified AYA aged 15-29 years with chronic digestive disorders who received ≥ 1 outpatient opioid prescription between March 2018 and December 2021, using Northwestern Medicine's Electronic Data Warehouse. Short-term persistent high-dose opioid use was defined as a daily mean of ≥ 50 MME/day for ≥ 7 consecutive days. Patients were categorized into high-dose vs. non-high-dose users. We examined demographic and clinical covariates (e.g., race/ethnicity, insurance status, psychiatric diagnoses, GI and non-GI pain diagnoses, concurrent medications) using descriptive and bivariate analyses. Risk factors for high-dose use were identified via multivariate logistic regression.
RESULTS: Among 2549 AYA patients, 12% met criteria for high-dose opioid use. Risk factors included older age within the cohort, benzodiazepine-opioid co-use, oxycodone use, and concurrent non-GI pain diagnoses (e.g., arthritis).
DISCUSSION: Nearly 12% of AYA with chronic digestive disorders who used opioids for ≥ 7 days received high-dose prescriptions. These findings underscore the need for safer prescribing guidelines tailored to this population. Future work should consider weight-based dosing thresholds and expanded datasets to monitor and reduce opioid-related harm in AYA with digestive disorders.